Low molecular weight heparin vs vitamin K antagonist (VKA)
All‐cause mortality (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters
Low‐molecular‐weight heparin (LMWH) showed no clear difference in all‐cause mortality (up to 3 months) compared with vitamin K antagonist (VKA) (low certainty).
1 finding from 1 review
- Anticoagulation for people with cancer and central venous catheters 2018 · Cochrane Headline outcomes onlyRR 0.94 [0.56, 1.59]3 studies · 561 participantsLow